Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma

Journal of Immunotherapy

Volumn 23, Issue 2, 2000, Pages 275-281

  Scheibenbogen, Carmen ^a   Schmittel, Alexander ^a   Keilholz, Ulrich ^a   Allgäuer, Thomas ^b   Hofmann, Udo ^b   Max, Regina ^b   Thiel, Eckhard ^b   Schadendorf, Dirk ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ELISPOT assay; Peptide; Tyrosinase; Vaccination

Indexed keywords

CYSTEINYLDOPA; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; MONOPHENOL MONOOXYGENASE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; CANCER REGRESSION; CANCER STAGING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEVER; HEADACHE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; MELANOMA; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VOMITING;

BONE NEOPLASMS; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MONOPHENOL MONOOXYGENASE; OLIGOPEPTIDES;

EID: 0034064242     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200003000-00012     Document Type: Article

References (23)

1. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5.
2. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1996; 3:37-44.
3. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-57.
4. Jaeger E, Ringhoffer M, Dienes HP, et al. GM-CSF enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67:54-62.
5. Cormier JN, Abati A, Fetsch P, et al. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunotherapy 1998; 21:27-31.
6. De Vries TJ, Fourkour A, Wobbes T, et al. Heterogenous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997; 57:3223-9.
7. Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994; 54:3124-6.
8. Schmittel A, Keilholz U, Max R, Thiel E, Scheibenbogen C. Induction of tyrosinase-reactive T cells by the treatment with DTIC, cisplatin, IFN-IL-2 in patients with metastatic melanoma. Int J Cancer 1999; 80:39-45.
9. Wölfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24:759-64.
10. Kittlesen DJ, Thompson LW, Gulden PH, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol 1998; 160:2099-2106.
11. Skipper J, Hendrickson R, Gulden P, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183:527-34.
12. Kang X, Kawakami Y, El-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995; 155:1343-8.
13. Brichard VG, Herman J, van Pel A, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1996; 26:224-30.
14. Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88:202-10.
15. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Her-2/neu peptide vaccines elicit T cell immunity to the her-2/neu protein in patients with breast and ovarian cancer. Proceedings of the American Society for Clinical Oncology (Abstract 375). J Clin Oncol 1998;17.
16. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon- ELISPOT-assay for quantification of peptide-specific T lymphocytes from peripheral blood. J Immunol Methods 1997; 210:167-74.
17. Scheibenbogen C, Lee KH, Stevanovic S, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFN--ELISPOT assay. Int J Cancer 1997; 71:932-6.
18. Blasczyk R, Hahn U, Wehling J, Huhn D, Salama A. Complete subtyping of the HLA-A locus by sequence-specific amplification followed by direct sequencing or single-strand conformation polymorphism analysis. Tissue Antigens 1995; 46:86-95.
19. Brossart P, Schmier J, Willhauck M, et al. A PCR-based method for quantitation of circulating melanoma cells. Cancer Res 1995; 55:4065-8.
20. Ito S, Kato T, Maruta K, Fujita K, Kurahashi T. Determination of DOPA, dopamine, and 5-SCD in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1984; 311:154-9.
21. Scheibenbogen C, Keilholz U, Mytilineos J, et al. HLA class I alleles and responsiveness to immunotherapy with IFN- and IL-2. Melanoma Res 1994; 4:191-4.
22. Lewis JJ, Janetzki S, Wang S, et al. Phase I trial of vaccination with tyrosinase peptide plus QS-21 in melanoma (Abstract 1650). J Clin Oncol 1998;17.
23. Lanzavecchia A. Immunology. Licence to kill. Nature 1998; 4:413-14.